Search

Displaying results 2941 - 2950 of 10000 in total
  1. Drug

    Elamipretide

    go.drugbank.com/drugs/DB11981
    ApprovedInvestigational

    [A274416] This interaction improves mitochondrial morphology and function.[L54036] In September 2025, the U.S. … Food and Drug Administration (FDA) granted accelerated approval for FORZINITY™ (elamipretide) to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.

    Categories: Amino Acids, Peptides, and Proteins
  2. Drug

    Sodium carbonate

    go.drugbank.com/drugs/DB09460
    ApprovedWithdrawn

    As a strong base, sodium hydroxide neutralizes gastric acid thereby acting as an antacid. … Sodium Carbonate is the disodium salt of carbonic acid with alkalinizing property. When dissolved in water, sodium carbonate forms carbonic acid and sodium hydroxide.

  3. Target

    Gremlin-1

    go.drugbank.com/bio_entities/BE0011799
    TargetHumans

    Can inhibit the growth or viability of normal cells but not transformed cells when is overexpressed (By similarity) … Cytokine that may play an important role during carcinogenesis and metanephric kidney organogenesis, as a BMP antagonist required for early limb outgrowth and patterning in maintaining the FGF4-SHH feedback

    Synonyms: Increased in high glucose protein 2, Down-regulated in Mos-transformed cells protein
  4. Drug

    Inavolisib

    go.drugbank.com/drugs/DB15275
    ApprovedInvestigational

    Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers. … [A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical

  5. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

    Categories: Hypnotics and Sedatives, Miscellaneous Anxiolytics Sedatives and Hypnotics
  6. Drug

    Etafedrine

    go.drugbank.com/drugs/DB11587
    Approved

    Etafedrine (INN) or ethylephedrine is a long-acting bronchodilator and has been an ingredient combined with other drugs in the brand names Nethaprin [A32757] and Dalmacol [L2568]. … It was previously available as both the free base and as the hydrochloride salt manufactured by Sanofi-Aventis (now Sanofi) has been discontinued [L2563].

  7. Drug

    Molybdenum

    go.drugbank.com/drugs/DB11137
    ApprovedInvestigational

    It is an essential trace dietary element and acts as a critical cofactor in several molybdenum-dependent enzymes that are involved in important cellular reactions and pathways, including xanthine oxidoreductase … Molybdenum is commonly used in metallurgy and other chemical applications however it has essential biological roles in organisms and microorganisms.

    Mixtures: Spectrum 2 Cap, Iron 25mg With Vit B-cmplx, Vit C, Cu & MoCategories: Diet, Food, and Nutrition
  8. Drug

    Tetraferric tricitrate decahydrate

    go.drugbank.com/drugs/DB14520
    ApprovedInvestigational

    Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. … [A25965] Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.[L9926]

    Mixtures: Maxine Vitamin and Mineral SupplementCategories: Drugs for Treatment of Hyperkalemia and Hyperphosphatemia
  9. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089] … Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pivoted toward oncology as a potent sensitizing

  10. Drug

    rhThrombin

    go.drugbank.com/drugs/DB04923
    ApprovedWithdrawn

    The production of recombinant proteins is not dependent on the availability of blood from animals or human donors and can be scaled-up to meet market demand. … rhThrombin (recombinant human thrombin) is being developed by ZymoGenetics, Inc. as a general aid to achieving hemostasis during surgery.